Table 4.
Hazard ratios (95% CIs) for death among pancreatic cancer case patients by combined categories of plasma metabolite levels and rs7874815 genotypes in ACO1*
| Metabolite | Tertiles | rs7874815 | |
|---|---|---|---|
| AA HR (95% CI) | AG/GG HR (95% CI) | ||
| Isocitrate | 1 | 1.0 | 1.47 (1.00 to 2.16) |
| 2 | 1.31 (0.84 to 2.05) | 2.42 (1.50 to 3.91) | |
| 3 | 1.64 (1.05 to 2.58) | 2.72 (1.65 to 4.49) | |
| Aconitate | 1 | 1.0 | 1.67 (1.14 to 2.45) |
| 2 | 1.16 (0.73 to 1.83) | 1.74 (1.08 to 2.80) | |
| 3 | 1.44 (0.92 to 2.25) | 2.67 (1.62 to 4.39) | |
| Citrate/ (isocitrate + aconitate) | 3 | 1.0 | 1.62 (1.10 to 2.40) |
| 2 | 1.64 (1.05 to 2.56) | 2.33 (1.44 to 3.79) | |
| 1 | 1.83 (1.14 to 2.92) | 3.32 (2.02 to 5.47) | |
* Adjusted for age at diagnosis (years, continuous), cohort (Health Professionals Follow-up Study, Nurses’ Health Study, Physicians’ Health Study, Women’s Health Initiative; also adjusts for sex), race/ethnicity (white, black, other, missing), stage at diagnosis (localized, locally advanced, metastatic, unknown), fasting time (<4, 4–8, 8–12, ≥12 hours, missing), and year of diagnosis (1984–1995, 1996–2005, 2006–2010). CI = confidence interval; HR = hazard ratio.